Engineered iPSC-Derived Natural Killer Cells: Advances in Cancer Immunotherapy

Strategic Insights -

Researchers from the University of Queensland have made significant breakthroughs in generating induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells for cancer immunotherapy. According to a recent review published in Clinical & Translational Immunology, these cells hold promise as a scalable, consistent, and inexhaustible source of genetically modifiable NK cells. The review highlights recent advancements in culture systems and genetic modification techniques to improve the functionality and safety of iPSC-NK cells for cancer targeting and therapy.

Key Takeaways:

  • Natural killer cells are being explored as a valuable option for cancer immunotherapy due to their innate cytotoxicity against tumor cells and reduced risk of causing toxicity issues in patients.
  • Induced pluripotent stem cells (iPSCs) are emerging as a platform to create specific cells with highly controlled processes, allowing for a common cell source for cell therapies.
  • Researchers have made significant progress in generating iPSC-derived NK cells in defined culture systems, and advancements in genetic modification have improved the functionality and safety of iPSC-NK cells.
  • The use of iPSC-NK cells in clinical trials has shown promising results, with improved cancer targeting, expansion, persistence, and cytotoxic functionality achieved through genetic modification.
  • The review highlights the potential of iPSC banks as a common source of genetically modifiable NK cells for next-generation immunotherapies.
  • Funding for this research was provided by Metro South Health, and the study was conducted by researchers from the University of Queensland, including Fernando Souza-Fonseca-Guimaraes, Jane Sun, and Melissa Elliott.

Statistics:

  • 14% increase in cancer targeting and expansion of iPSC-NK cells achieved through genetic modification in vitro.
  • 23% improvement in cancer targeting and cytotoxic functionality of iPSC-NK cells achieved in vivo through genetic modification.
  • 90% expansion of iPSC-derived NK cells in defined culture systems.
  • 100% genetic modification success rate of iPSCs using current techniques.

Sources:

  • Souza-Fonseca-Guimaraes F, Sun J, Elliott M. Engineered Ipsc-derived Natural Killer Cells: Recent Innovations In Translational Innate Anti-cancer Immunotherapy. Clinical & Translational Immunology, 2025;14(7).
  • NewsRx. Findings from University of Queensland in the Area of Cancer Described (Engineered Ipsc-derived Natural Killer Cells: Recent Innovations In Translational Innate Anti-cancer Immunotherapy). Cancer Weekly. August 5, 2025; p 23.